No Data
No Data
Shanzi Hi-Tech (000981.SZ) announced first-quarter results, turning a loss into a profit of 458 million yuan
Shanzi Hi-Tech (000981.SZ) released its report for the first quarter of 2024. The company's revenue was 11.8...
Sensteed Hi-Tech Group (SZSE:000981 Investor Five-year Losses Grow to 66% as the Stock Sheds CN¥1.0b This Past Week
We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly. To wit, the Sensteed Hi-Tech Group (SZSE:000981) share price managed to fall 66%
Shanzi Co., Ltd. (000981.SZ): Proposed to change the name of the securities to “Shanzi Hi-Tech”
Gelonghui Co., Ltd. (000981.SZ) announced that the company's stock abbreviation was changed from “Shanzi Shares” to “Shanzi Hi-Tech”. The opening period was March 25, 2024; the company's stock code “000981” remains unchanged.
There's Reason For Concern Over Sensteed Hi-Tech Group's (SZSE:000981) Massive 27% Price Jump
Those holding Sensteed Hi-Tech Group (SZSE:000981) shares would be relieved that the share price has rebounded 27% in the last thirty days, but it needs to keep going to repair the recent damage it ha
5.06% of the shares held by Xiong Jikai, the majority shareholder of Shanzi Co., Ltd. (000981.SZ), are pending freezing
Zhitong Finance App News, Shanzi Co., Ltd. (000981.SZ) issued an announcement. Recently, the company learned through the China Securities Registration and Settlement Co., Ltd. system inquiry that the company shares held by Xiong Jikai, a shareholder holding 5% or more of the company's shares, have been judicially frozen and pending freezing. This time, 50.6 million shares of the company's shares are pending freezing, accounting for 12.07% of the company's total share capital.
Hehua Co., Ltd. (000953.SZ): Shanzi Co., Ltd. has no business dealings with the company, and its business changes will not affect the company
On March 14, Gelonghui Co., Ltd. (000953.SZ) said on the investor interactive platform that Shanzi Co., Ltd. has no business dealings with the company, and its business changes will not affect the company. The company's current business is still mainly pharmaceutical intermediates, and will further expand in the development of new products and contract customized production.
No Data